|
|
BRIEF COMMUNICATION |
|
Year : 2011 | Volume
: 59
| Issue : 6 | Page : 512-514 |
|
Natamycin in the treatment of keratomycosis: Correlation of treatment outcome and in vitro susceptibility of fungal isolates
Linu Pradhan1, Savitri Sharma1, Suma Nalamada2, Srikant K Sahu1, Sujata Das1, Prashant Garg2
1 L. V. Prasad Eye Institute, Bhubaneswar, Orissa, India 2 L. V. Prasad Eye Institute, Hyderabad, A.P., India
Date of Submission | 19-Oct-2010 |
Date of Acceptance | 05-Jun-2011 |
Date of Web Publication | 19-Oct-2011 |
Correspondence Address: Savitri Sharma L. V. Prasad Eye Institute, Patia, Bhubaneswar - 751 024, Orissa India
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/0301-4738.86328
In this study, 60 fungal isolates from 60 patients with fungal keratitis were tested in vitro for their susceptibility to natamycin and the mean minimum inhibitory concentrations of natamycin (MICn) were correlated with clinical outcome. The mean MICn for various groups of fungi from patients with either early (<10 days) or late (≥10 days) presentation was correlated with the outcome. Aspergillus flavus showed resistance to natamycin with a high mean MICn (>16 μg/ml). While the clinical response in all patients with early A. flavus keratitis was good it was poor in late cases (5/8 patients, 62.5%). Fusarium species, Acremonium species and dematiaceous fungi were sensitive with low mean MICn (Fusarium: 5.7-7.2 μg/ml, Acremonium: 5.7-6.8 μg/ml, dematiaceous: (1.6-4 μg/ml). However, 46.6% (7/15) patients in Fusarium and 57.1% (4/7) in Acremonium group needed keratoplasty. We conclude that despite susceptibility of most fungal species causing keratitis to natamycin, the treatment outcome is poor in advanced fungal keratitis. Keywords: Keratomycosis, minimum inhibitory concentration, natamycin, susceptibility, treatment outcome
How to cite this article: Pradhan L, Sharma S, Nalamada S, Sahu SK, Das S, Garg P. Natamycin in the treatment of keratomycosis: Correlation of treatment outcome and in vitro susceptibility of fungal isolates. Indian J Ophthalmol 2011;59:512-4 |
Keratomycosis is the leading cause of ocular morbidity throughout the world and fungi are the principal etiological agents of corneal ulceration in India. [1],[2],[3] Different classes of antifungal drugs used for treatment of fungal keratitis include polyenes, triazoles, and echinocandins. [2] Of these, natamycin is the mainstay of treatment and is widely used in India. However, treatment outcome in fungal ulcers tends to be poorer compared to bacterial and Acanthamoeba keratitis. [1],[3]
In the non-ophthalmic literature a fairly wide range of antifungal susceptibility test results are available for prediction of clinical outcome in fungal infections. [4] In contrast, such information is lacking in keratomycosis. Only a limited number of antifungal susceptibility testing of ocular isolates has been reported [5],[6] and except for one none have correlated with response to treatment in the patients. [6] In the present study 60 fungal isolates from 60 patients with fungal keratitis were tested in vitro for their susceptibility to natamycin eye drop and the mean minimum inhibitory concentrations (MIC) were correlated with the clinical outcome with topical 5% natamycin eye drops.
Materials and Methods | | |
In this prospective, non randomized interventional study corneal scrapings from patients with microbial keratitis were processed and interpreted as per our institutional protocol. [3] Consent was obtained from all patients. Taking appropriate laboratory precautions all significant fungal growth were tested for their susceptibility to natamycin eye drop (Sun pharmaceutical Ind. Ltd, Mumbai, India) by the previously described microbroth dilution method. [7]
All patients received intensive treatment with one hourly 5% natamycin eye drops round the clock in the affected eye for the first three days with subsequent modification as per response. Twenty five patients were given oral ketoconazole (200 mg twice daily) and two patients received oral fluconazole (150 mg twice daily). Clinical outcome at one month was considered for analysis. An ulcer was defined either completely healed or resolving (reduction in infiltrate size) or worsened (increase in infiltrate size, keratoplasty). Since the treatment outcome is known to be affected by severity of disease the mean MIC of natamycin for different groups of fungi for patients presenting with in 10 days (early onset) or after 10 days (late onset) of symptoms were correlated with the clinical outcome. [8]
Results | | |
Fungal species wise comparison of mean MIC of natamycin with treatment outcome was made among the patients with early and late onset disease [Table 1]. A. flavus (n = 13) showed the highest mean MIC (early-17.7 μg/ml, late-20.0 μg/ml) suggesting lowest susceptibility to natamycin. Excluding the patients lost to follow up five out of 6 patients (83.3%) had poor clinical response in the late group (A. flavus) while none had worsened in the early group (A. flavus). A. fumigatus, in contrast, showed high susceptibility to natamycin in vitro with mean MIC of 4.12 μg/ml. The clinical outcome, however, was poor in the cases that presented late. MIC of natamycin was relatively low for Fusarium species with mean MIC between 5.7-8 μg/ml. Nevertheless, 7 out of 14 patients (50.0%, 1 lost to follow up) needed penetrating keratoplasty to control the infection suggesting poor clinical response to natamycin. Among the dematiaceous fungi, Curvularia species were isolated in four patients and natamycin showed low MIC against these isolates (mean MIC in early - 1.6 μg/ml, late - 2 μg/ml). | Table 1: Treatment outcome of patients with early (<10 days) and late (>10 days) onset of fungal keratitis caused by various groups of fungi and their correlation with MIC of natamycin
Click here to view |
Discussion | | |
A notable publication by Prajna et al., has convincingly shown that eye drop preparations are an alternative to pharmaceutical grade natamycin (not available to most laboratories) for testing antifungal susceptibility. [7] This study applied the same technique to evaluate the MIC of natamycin against various isolates of fungi from corneal scrapings of patients with mycotic keratitis. Owing to a small sample size in various groups of fungi, the mean MIC [9] was considered for comparison rather than MIC 90 or MIC 50 . Susceptibility breakpoints for natamycin have not been described so far in CLSI guidelines, however, MIC of 16 μg/ml or less is considered to indicate susceptibility of a fungal isolate. [7] This study reassuringly found low MIC of natamycin (≤16 μg/ml) in all fungal isolates tested except A. flavus. A. flavus associated with keratitis is a particularly virulent fungus and is known to be associated with poor outcome in keratomycosis. [8] Apart from the toxins, [10] its perilous status is compounded by its resistance to natamycin. It is not known whether this resistance is inherent to this species.
All isolates of Fusarium species were sensitive to natamycin but that did not translate to good clinical outcome in patients with Fusarium keratitis irrespective of early or late presentation. This probably points to the well known fact of poor penetration of natamycin especially in presence of advanced fungal keratitis affecting deeper layers of the cornea. Most encouraging results were obtained with respect to dematiaceous fungi [Table 1]. Scedosporium apiospermum and Bipolaris species showed susceptibility to natamycin with low MIC as well as favourable response to treatment with natamycin. However, both patients with Exerohilum species infection had presented late and showed poor response. Good treatment outcome in keratitis caused by dematiaceous fungi can be attributed to low virulence of dematiaceous fungi and their tendency to remain in the superficial tissues of cornea for long. [11] This study shows that a low MIC of natamycin (susceptible fungi) was not always associated with good treatment outcome with natamycin in fungal keratitis. As is well known, a large number of factors affect success or failure of medical therapy of fungal keratitis, severity of infection being one of them. [8] Our treatment protocol for fungal keratitis includes systemic antifungals for patients with the ulcer more than 6 mm in diameter or extending beyond anterior half of the stroma or when there is hypopyon. Systemic antifungal therapy given in some of the patients in this study may be a confounding factor which was not analyzed and is one of the limitations of this study. Using logistic regression Shapiro et al., showed that a two fold increase in MIC results in 47% reduction in the odds of healing. [6] However, results of the present study suggest that such a conclusion may be too simplistic and a considerably large study addressing multiple factors would be necessary to determine the effect of various parameters on the treatment outcome of fungal keratitis.
Despite the limitation of small sample size in each group of fungi and statistically non significant results, we believe that our results are clinically significant. The susceptibility of A. flavus to natamycin is particularly poor and patients with this infection may require aggressive treatment, closer follow up and early surgical intervention. In vitro susceptibility of most other species of fungi, such as Fusarium spp., A. fumigatus, Acremonium spp., S. apiospermum, Bipolaris spp., Curvularia spp. etc., to natamycin may account for good clinical response when the intervention occurs early in the disease.
References | | |
1. | Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol 2004;15:321-7. [ PUBMED] [ FULLTEXT] |
2. | Thomas PA. Current perspective in ophthalmic mycosis. Clin Microbiol Rev 2003;16:730-97. [ PUBMED] [ FULLTEXT] |
3. | Goinathan U, Sharma S, Garg P, Rao GN. Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: Experience of over a decade. Indian J Ophthalmol 2009;57:273-9. |
4. | Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002;35:982-9. [ PUBMED] [ FULLTEXT] |
5. | Gopinathan U, Garg P, Fernandes M, Sharma S, Sreedharan A, Rao GN. The epidemiological features and laboratory results of fungal keratitis: A 10-year review at a referral eye care center in south India. Cornea 2002;21:555-9. |
6. | Shapiro BL, Lalitha P, Loh AR, Fothergill AW, Prajna NV, Srinivasan M, et al. Susceptibility testing and clinicaloutcome in fungal keratitis. Br J Ophthalmol 2010;94:383-4. |
7. | Lalitha P, Vijaykumar R, Prajna NV, Fothergill AW. In vitro natamycin susceptibility of ocular isolates of Fusarium and Aspergillus species: Comparison of commercially formulated natamycin eye drops to pharmaceutical-grade powder. J Clin Microbiol 2008;46:3477-8. [ PUBMED] [ FULLTEXT] |
8. | Lalitha P, Prajna NV, Kabra A, Mahadevan K, Srinivasan M. Risk factors for treatment outcome in fungal keratitis. Ophthalmology 2006;113:526-30. [ PUBMED] [ FULLTEXT] |
9. | Tavanti A, Hensgens LA, Mogavero S, Majoros L, Senesi S, Campa M. Genotypic and phenotypic properties of Candida parapsilosis sensu strictu strains isolated from different geographic regions and body sites. BMC Microbiol 2010;10:203. [ PUBMED] [ FULLTEXT] |
10. | Leema G, Kaliamurthy J, Geraldine P, Thomas PA. Keratitis due to Aspergillus flavus: Clinical profile, molecular identification of fungal strains and detection of aflatoxin production. Mol Vis 2010;16:843-54. [ PUBMED] [ FULLTEXT] |
11. | Vemuganti GK, Garg P, Gopinathan U, Naduvilath TJ, John RK, Rajeev B, et al. Evaluation of agent and host factors in progression of mycotic keratitis: A histological and microbiological study of 167 buttons. Ophthalmology 2002;109:1538-46. |
[Table 1]
This article has been cited by | 1 |
Antibiotic susceptibility in Endophthalmitis Management Study and intravitreal antibiotic practice trend in India—EMS Report #5 |
|
| Taraprasad Das, Suchita Pandey, Joveeta Joseph, Jay Sheth, Akash Belenje, Umesh C. Behera, Aditya Kapoor, Rudvij Pandya, Vivek Pravin Dave | | Graefe's Archive for Clinical and Experimental Ophthalmology. 2024; | | [Pubmed] | [DOI] | | 2 |
Antifungal Efficacy of Luliconazole in an Experimental Rabbit Model of Fungal Keratitis Caused by Fusarium solani |
|
| Sho Arimoto, Katsuhiro Inagaki, Daisuke Todokoro, Takashi Suzuki, Koichi Makimura, Tomoko Ishino | | Mycopathologia. 2023; | | [Pubmed] | [DOI] | | 3 |
Corneal targeted Amorolfine HCl-mixed micelles for the management of ocular candidiasis: Preparation, in vitro characterization, ex vivo and in vivo assessments |
|
| Eman M. Abd-Elmonem, Amna MA. Makky, Asem Anter, Wessam H. Abd-Elsalam, Islam A. Khalil | | Journal of Drug Delivery Science and Technology. 2023; : 104614 | | [Pubmed] | [DOI] | | 4 |
Microbiology Profile of COVID-19-Associated Rhino-Orbital Mucormycosis Pathogens in South India |
|
| Esther Sheba, Savitri Sharma, Dilip Kumar Mishra, Tarjani Vivek Dave, Anasua Ganguly Kapoor, Joveeta Joseph | | The American Journal of Tropical Medicine and Hygiene. 2023; 108(2): 377 | | [Pubmed] | [DOI] | | 5 |
Clinical and Mycological Features of Fungal Keratitis: A Retrospective Single-Center Study (2012-2018) |
|
| Ibrahim Inan Harbiyeli, Elif Erdem, Nuhkan Görkemli, Astan Ibayev, Hazal Kandemir, Arbil Açikalin, Macit Ilkit, Meltem Yagmur | | Turkish Journal of Ophthalmology. 2022; 52(2): 75 | | [Pubmed] | [DOI] | | 6 |
Elucidating the clinical, microbiological and molecular diagnostic aspects of Macrophomina phaseolina keratitis |
|
| Lalit Kishore Ahirwar, Esther Sheba, Saumya Jakati, Rajagopalaboopathi Jayasudha, Shalem Raj Padakandla, Bhupesh Bagga, Savitri Sharma | | Medical Mycology. 2022; 60(4) | | [Pubmed] | [DOI] | | 7 |
Trends in the Microbiological Spectrum of Nonviral Keratitis at a Single Tertiary Care Ophthalmic Hospital in India: A Review of 30 years |
|
| Joveeta Joseph, Roshini Karoliya, Esther Sheba, Savitri Sharma, Bhupesh Bagga, Prashant Garg | | Cornea. 2022; Publish Ah | | [Pubmed] | [DOI] | | 8 |
Antifungal Combination Eye Drops for Fungal Keratitis Treatment |
|
| Victoria Díaz-Tomé, Carlos Bendicho-Lavilla, Xurxo García-Otero, Rubén Varela-Fernández, Manuel Martín-Pastor, José Llovo-Taboada, Pilar Alonso-Alonso, Pablo Aguiar, Miguel González-Barcia, Anxo Fernández-Ferreiro, Francisco J. Otero-Espinar | | Pharmaceutics. 2022; 15(1): 35 | | [Pubmed] | [DOI] | | 9 |
Molecular Identification, Phylogeny and Antifungal Susceptibilities of Dematiaceous Fungi isolated from Human Keratomycosis |
|
| Arumugam Mythili, Coimbatore Subramanian Shobana, Krisztina Krizsán, Anamangadan Shafeeq Hassan, Annanthode Balakrishnan Sangeetha, Mónika Homa, Tamás Papp, Raed Abdullah Alharbi, AyoubAl Othaim, Alaa Baazeem, Kanesan Panneer Selvam, Moorthy Kannaiyan, Csaba Vágvölgyi, László Kredics, Palanisamy Manikandan | | Journal of Infection and Public Health. 2022; | | [Pubmed] | [DOI] | | 10 |
Antibiotics - (Vol. 16, No. 2, Full Issue) |
|
| Harish C. Gugnani | | Asia-Pacific Biotech News. 2021; 16(02): 291 | | [Pubmed] | [DOI] | | 11 |
Study of keratomycosis at a tertiary care teaching hospital |
|
| Veluri Gayathri, Ami Jeswin | | IP International Journal of Medical Microbiology and Tropical Diseases. 2021; 7(2): 65 | | [Pubmed] | [DOI] | | 12 |
Fusarium Keratitis—Review of Current Treatment Possibilities |
|
| Marek Szalinski, Aleksandra Zgryzniak, Izabela Rubisz, Malgorzata Gajdzis, Radoslaw Kaczmarek, Joanna Przezdziecka-Dolyk | | Journal of Clinical Medicine. 2021; 10(23): 5468 | | [Pubmed] | [DOI] | | 13 |
Rabbit Fungal Keratitis Model of Fusarium solani Tested Against Three Commercially Available Antifungal Drugs |
|
| Thet Tun Aung, Wei Hong Jeff Chor, Myoe Naing Lynn, Anita Sook Yee Chan, Donald T.H. Tan, Roger W. Beuerman | | Eye & Contact Lens: Science & Clinical Practice. 2020; 46(5): 274 | | [Pubmed] | [DOI] | | 14 |
Sarocladium
and
Acremonium
infections: New faces of an old opportunistic fungus
|
|
| Alba Pérez-Cantero, Josep Guarro | | Mycoses. 2020; 63(11): 1203 | | [Pubmed] | [DOI] | | 15 |
Epidemiology of Aspergillus species causing keratitis in Mexico |
|
| Abdullah M. S. Al-Hatmi, Marino Alcantara Castro, G. Sybren de Hoog, Hamid Badali, Victor Flores Alvarado, Paul E. Verweij, Jacques F. Meis, Virginia Vanzzini Zago | | Mycoses. 2019; 62(2): 144 | | [Pubmed] | [DOI] | | 16 |
Natamycin and Voriconazole Exhibit Synergistic Interactions with Nonantifungal Ophthalmic Agents against
Fusarium
Species Ocular Isolates
|
|
| Christiaan A. Rees, Ruina Bao, Michael E. Zegans, Robert A. Cramer | | Antimicrobial Agents and Chemotherapy. 2019; 63(7) | | [Pubmed] | [DOI] | | 17 |
Natamycin and Azithromycin Are Synergistic
In Vitro
against Ocular Pathogenic Aspergillus flavus Species Complex and Fusarium solani Species Complex Isolates
|
|
| Haoyi Guo, Lutan Zhou, Yi He, Chuanwen Gao, Lei Han, Yan Xu | | Antimicrobial Agents and Chemotherapy. 2018; 62(7) | | [Pubmed] | [DOI] | | 18 |
Short Synthetic a-Helical-Forming Peptide Amphiphiles for Fungal Keratitis Treatment In Vivo |
|
| Hong Wu, Shaoqiong Liu, Nikken Wiradharma, Zhan Yuin Ong, Yan Li, Yi Yan Yang, Jackie Y. Ying | | Advanced Healthcare Materials. 2017; 6(6) | | [Pubmed] | [DOI] | | 19 |
Changing trends in fungal and bacterial profile of infectious keratitis at a tertiary care hospital: A six-year study |
|
| Priyamvada Roy, Shukla Das, N.P. Singh, Rumpa Saha, Garima Kajla, K. Snehaa, V.P. Gupta | | Clinical Epidemiology and Global Health. 2017; 5(1): 40 | | [Pubmed] | [DOI] | | 20 |
Ocular infections caused by Candida species: Type of species, in vitro susceptibility and treatment outcome |
|
| SR Motukupally, VR Nanapur, KN Chathoth, SI Murthy, RR Pappuru, A Mallick, S Sharma | | Indian Journal of Medical Microbiology. 2015; 33(4): 538 | | [Pubmed] | [DOI] | | 21 |
Filamentous fungal infections of the cornea: a global overview of epidemiology and drug sensitivity |
|
| László Kredics,Venkatapathy Narendran,Coimbatore Subramanian Shobana,Csaba Vágvölgyi,Palanisamy Manikandan | | Mycoses. 2015; 58(4): 243 | | [Pubmed] | [DOI] | | 22 |
Clinical utility of caspofungin eye drops in fungal keratitis |
|
| Chin Fen Neoh,Mark Daniell,Sharon C.-A. Chen,Kay Stewart,David C.M. Kong | | International Journal of Antimicrobial Agents. 2014; | | [Pubmed] | [DOI] | | 23 |
Effect of Voriconazole and Ultraviolet-A Combination Therapy Compared to Voriconazole Single Treatment onFusarium solaniFungal Keratitis |
|
| Kyoung Sub Choi,Sang Chul Yoon,Tyler Hyung Taek Rim,Soo Jung Han,Eun-Do Kim,Kyoung Yul Seo | | Journal of Ocular Pharmacology and Therapeutics. 2014; 30(5): 381 | | [Pubmed] | [DOI] | | 24 |
Argon Laser Phototherapy in the Treatment of Refractory Fungal Keratitis |
|
| Fernando Pellegrino,María Alejandra Carrasco | | Cornea. 2013; 32(1): 95 | | [Pubmed] | [DOI] | | 25 |
Fusarium Keratitis |
|
| Rafael A. Oechsler,Michael R. Feilmeier,Darlene Miller,Wei Shi,Ana Luisa Hofling-Lima,Eduardo C. Alfonso | | Cornea. 2013; 32(5): 667 | | [Pubmed] | [DOI] | | 26 |
Epidemiology ofAspergilluskeratitis at a tertiary care eye hospital in South India and antifungal susceptibilities of the causative agents |
|
| Palanisamy Manikandan,János Varga,Sándor Kocsubé,Raghavan Anita,Rajaraman Revathi,Tibor Mihály Németh,Venkatapathy Narendran,Csaba Vágvölgyi,Kanesan Panneer Selvam,Coimbatore Subramanian Shobana,Yendremban Randhir Babu Singh,László Kredics | | Mycoses. 2013; 56(1): 26 | | [Pubmed] | [DOI] | | 27 |
Fusariumkeratitis in South India: causative agents, their antifungal susceptibilities and a rapid identification method for theFusarium solanispecies complex |
|
| Mónika Homa,Coimbatore S. Shobana,Yendrembam R. B. Singh,Palanisamy Manikandan,Kanesan P. Selvam,László Kredics,Venkatapathy Narendran,Csaba Vágvölgyi,László Galgóczy | | Mycoses. 2013; 56(5): 501 | | [Pubmed] | [DOI] | | 28 |
Antifungal effect of ophthalmic preservatives phenylmercuric nitrate and benzalkonium chloride on ocular pathogenic filamentous fungi |
|
| Yan Xu,Yi He,Xiaohua Li,Chuanwen Gao,Lutan Zhou,Shengtao Sun,Guangren Pang | | Diagnostic Microbiology and Infectious Disease. 2013; 75(1): 64 | | [Pubmed] | [DOI] | | 29 |
Microscopic Evaluation, Molecular Identification, Antifungal Susceptibility, and Clinical Outcomes in Fusarium, Aspergillus and, Dematiaceous Keratitis |
|
| Devarshi U. Gajjar,Anuradha K. Pal,Bharat K. Ghodadra,Abhay R. Vasavada | | BioMed Research International. 2013; 2013: 1 | | [Pubmed] | [DOI] | | 30 |
In VitroAntifungal Activity of Silver Nanoparticles Against Ocular Pathogenic Filamentous Fungi |
|
| Yan Xu,Chuanwen Gao,Xiaohua Li,Yi He,Lutan Zhou,Guangren Pang,Shengtao Sun | | Journal of Ocular Pharmacology and Therapeutics. 2013; 29(2): 270 | | [Pubmed] | [DOI] | | 31 |
In Vitro Susceptibility of Filamentous Fungal Isolates From a Corneal Ulcer Clinical Trial |
|
| Prajna Lalitha,Catherine Q. Sun,N. Venkatesh Prajna,Rajarathinam Karpagam,Geetha Manoharan,Kieran S. O’Brien,Vicky Cevallos,Stephen D. McLeod,Nisha R. Acharya,Thomas M. Lietman | | American Journal of Ophthalmology. 2013; | | [Pubmed] | [DOI] | | 32 |
FEATURES |
|
| | | Asia-Pacific Biotech News. 2012; 16(02): 15 | | [Pubmed] | [DOI] | |
|
|
|
|